Another study by Zhang et al. provided valuable insights into the real-world effectiveness and safety profile of neoadjuvant immunotherapy with a single agent PD-1 inhibitor in dMMR/MSI-H colon and rectal cancer, contributing to the growing body of evidence supporting the use of immunotherapy in this context [33]. The gene discussed is PDCD1; the disease is rectal cancer.